Receptor variation influences fingolimod efficacy in mouse multiple sclerosis models

Multiple sclerosis (MS) is an autoimmune disorder that results in demyelination of neurons. The FDA-approved drug fingolimod (Gilenya, FTY-720) modulates signaling by the bioactive lipid sphingosine-1-phosphate (S1P), which is linked to MS pathogenesis. Fingolimod treatment reduces relapse rates and neurologic disability in many individuals with MS; however, the drug is less effective in some patients.

In this issue of JCI Insight, May Han of Stanford University and colleagues tested the hypothesis that genetic variants of the that responds to S1P, S1PR1, may influence the efficacy of fingolimod. In mouse MS models, fingolimod protected control mice from central nervous system damage, but was not effective in animals expressing an S1PR1 variant that could not be modified by phosphorylation.

Mutant animals had elevated expression of CCR6, a molecule that promotes migration of inflammatory cells, in the central nervous system. Treatment of these mice with fingolimod and an antibody targeting CCR6 delayed disease progression.

The results of this study indicate that S1P1R variation may underlie differential patient responses to fingolimod treatment.

Explore further

Multiple sclerosis drug may one day treat colorectal cancer

More information: Hsing-Chuan Tsai et al, Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY720 during neuroinflammation, JCI Insight (2016). DOI: 10.1172/jci.insight.86462
Provided by JCI Journals
Citation: Receptor variation influences fingolimod efficacy in mouse multiple sclerosis models (2016, June 16) retrieved 27 September 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors